-
ALSO READ
Australia receives over 142,000 doses of Pfizer coronavirus vaccine
Hong Kong approves Sinovac Biotech's Covid-19 vaccine for emergency use
US secures 200 million more doses of Moderna, Pfizer Covid-19 vaccines
Novavax vaccine seems 89% effective against coronavirus in UK study
Covid-19: Pfizer vaccine gets final nod in Japan, to be rolled out soon
-
Drugmaker Johnson & Johnson says it will be able to provide 20 million US doses of its single-shot COVID-19 vaccine by the end of March, assuming it gets the greenlight from federal regulators.
J&J disclosed the figure in written testimony ahead of a Congressional hearing on Tuesday looking at the country's vaccine supply. White House officials cautioned last week that initial supplies of J&J's vaccine would be limited.
The company reiterated that it will have capacity to provide 100 million vaccine doses to the US by the end of June. That supply will help government officials reach the goal of having enough injections to vaccinate most adult Americans later this year. On a global scale the company aims to produce 1 billion doses this year.
US health regulators are still reviewing the safety and effectiveness of the shot and a decision to allow its emergency use is expected later this week. J&J's vaccine would be the first in the US that requires only a single shot.
Currently available vaccines from Pfizer and Moderna require two doses spaced several weeks apart. Executives from both companies and two other vaccine makers will also testify at Tuesday's hearing.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU